This project is to conduct preclinical research into a promising new rapid-acting antidepressant. The standard of care in treating depression are selective serotonin reuptake inhibitors (SSRIs). A major drawback of SSRIs is that they are rarely effective in reducing suicidal ideation and suicidal behaviour during early treatment, particularly in young patients. Suicide is the leading cause of death in 20-34 year olds in the UK, and over 6000 suicides are registered in the UK each year. As many as 75% of suicide cases are associated with depression. This project builds on academic research which identifies a rapid-acting antidepressant which shows promise as a therapy to reduce suicidality in major depression patients. Very little is known about the physical form of the drug, or its suitability to pharmaceutical formulation. The outcome of this project is to understand the technical avenues available to prepare suitable dosage forms to investigate this drug in humans, paving the way for clinical trials.